Tg Therapeutics (TGTX) Net Income towards Common Stockholders: 2009-2024
Historic Net Income towards Common Stockholders for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to $23.4 million.
- Tg Therapeutics' Net Income towards Common Stockholders rose 10006.23% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 3212.81%. This contributed to the annual value of $23.4 million for FY2024, which is 84.52% up from last year.
- Latest data reveals that Tg Therapeutics reported Net Income towards Common Stockholders of $23.4 million as of FY2024, which was up 84.52% from $12.7 million recorded in FY2023.
- In the past 5 years, Tg Therapeutics' Net Income towards Common Stockholders ranged from a high of $23.4 million in FY2024 and a low of -$348.1 million during FY2021.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was $12.7 million (2023), whereas its average is -$62.6 million.
- Per our database at Business Quant, Tg Therapeutics' Net Income towards Common Stockholders crashed by 60.56% in 2020 and then surged by 105.66% in 2023.
- Tg Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$279.9 million in 2020, then decreased by 24.36% to -$348.1 million in 2021, then surged by 35.70% to -$223.8 million in 2022, then surged by 105.66% to $12.7 million in 2023, then spiked by 84.52% to $23.4 million in 2024.